Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314

There are no predictive biomarkers in clinical use for the neoadjuvant treatment of bladder cancer. Here we report on a recent randomized phase 2 trial validating the identification of predictive biomarkers using cell lines in the absence of patient response data.

Saved in:
Bibliographic Details
Published in:European urology focus 2022-05, Vol.8 (3), p.648-650
Main Authors: Dancik, Garrett M., Theodorescu, Dan
Format: Article
Language:English
Subjects:
Biomarkers
Cell Line
Humans
Neoadjuvant Therapy
Urinary Bladder Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are no predictive biomarkers in clinical use for the neoadjuvant treatment of bladder cancer. Here we report on a recent randomized phase 2 trial validating the identification of predictive biomarkers using cell lines in the absence of patient response data.
ISSN:2405-4569
2405-4569
DOI:10.1016/j.euf.2022.03.013